GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (NAS:ABCL) » Definitions » Price-to-Owner-Earnings

AbCellera Biologics (AbCellera Biologics) Price-to-Owner-Earnings : (As of Jun. 01, 2024)


View and export this data going back to 2020. Start your Free Trial

What is AbCellera Biologics Price-to-Owner-Earnings?

As of today (2024-06-01), AbCellera Biologics's share price is $3.93. AbCellera Biologics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for AbCellera Biologics's Price-to-Owner-Earnings or its related term are showing as below:


ABCL's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 32.61
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-01), AbCellera Biologics's share price is $3.93. AbCellera Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.52. Therefore, AbCellera Biologics's PE Ratio for today is At Loss.

As of today (2024-06-01), AbCellera Biologics's share price is $3.93. AbCellera Biologics's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.52. Therefore, AbCellera Biologics's PE Ratio without NRI for today is At Loss.

During the past 6 years, AbCellera Biologics's highest PE Ratio without NRI was 19633.33. The lowest was 0.00. And the median was 21.45.


AbCellera Biologics Price-to-Owner-Earnings Historical Data

The historical data trend for AbCellera Biologics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Price-to-Owner-Earnings Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

AbCellera Biologics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AbCellera Biologics's Price-to-Owner-Earnings

For the Biotechnology subindustry, AbCellera Biologics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbCellera Biologics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where AbCellera Biologics's Price-to-Owner-Earnings falls into.



AbCellera Biologics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

AbCellera Biologics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3.93/-0.55
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbCellera Biologics  (NAS:ABCL) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


AbCellera Biologics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


AbCellera Biologics (AbCellera Biologics) Business Description

Traded in Other Exchanges
Address
2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Executives
John S. Montalbano director C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Michael R Hayden director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Veronique Lecault director, officer: Chief Operating Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Thermopylae Holdings Ltd. 10 percent owner 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Booth officer: Chief Financial Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Lo director C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
John Hamer director, 10 percent owner PO BOX 14528, RESEARCH TRIANGLE PARK NC 27709-4528
Ester Falconer officer: Chief Technology Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Hansen Carl L. G. director, 10 percent owner, officer: Chief Executive Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Tryn Stimart officer: Chief Legal Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Peter Thiel director 9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Dcvc Bio, L.p. 10 percent owner 317 UNIVERSITY AVENUE, SUITE 200, PALO ALTO CA 94301
Dcvc Bio Gp, Llc 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Zachary Bogue 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Matthew Ocko 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301